However, as the CHC levels identified based upon dual expression of gp100 and HTR2B were predictive of clinical outcome (progression to metastasis; overall survival), it is also possible that this result simply reflects the insufficiency of tumor, node, metastasis staging to predict disease progression on an individual patient basis in uveal melanoma, a cancer in which lymphatic spread is exceptionally rare. The gene discussed is HTR2B; the disease is cancer.